Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring rifamycin cytotoxic potential through targeted liposomal formulations.

International journal of pharmaceutics·2026
Same author

Improved photocatalytic activity and enhanced germination rate of <i>Oryza sativa</i> and urea sensor development utilizing fabricated NiO·SrCO<sub>3</sub>·ZnO nanomaterials.

RSC advances·2025
Same author

Hybrid micellar preparations for co-delivery of PARP-1 siRNA and quercetin for cataract treatment.

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Disulfiram-containing polymeric nanocapsules with anticancer activity for cancer treatment.

International journal of pharmaceutics·2024
Same author

Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model.

Scientific reports·2024
Same author

Recent strategies to overcome breast cancer resistance.

Critical reviews in oncology/hematology·2024

Related Experiment Video

Updated: Jun 14, 2025

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.4K

Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy.

Md Abdus Subhan1,2, Vladimir P Torchilin3,4

  • 1Division of Nephrology, University of Rochester, 601 Elmwood Ave, Rochester, NY 14642, USA.

Bioengineering (Basel, Switzerland)
|August 29, 2024
PubMed
Summary

Triple-negative breast cancer (TNBC) is aggressive, lacking targeted therapy options. Nanomaterial-based siRNA delivery offers a promising approach to downregulate key genes, improving prognosis and reducing mortality in TNBC patients.

Keywords:
biomaterialsnanomaterialssiRNAtargeted therapytriple-negative breast cancer

More Related Videos

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.9K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

341

Related Experiment Videos

Last Updated: Jun 14, 2025

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.4K
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

10.9K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

341

Area of Science:

  • Oncology
  • Biotechnology
  • Nanomedicine

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis.
  • TNBC lacks specific molecular targets (ER, PR, HER2), complicating targeted therapy.
  • Current treatments like chemotherapy face challenges of drug resistance and recurrence.

Purpose of the Study:

  • To review advances in nanomaterial- and nanobiomaterial-based siRNA delivery platforms for TNBC therapy.
  • To explore targeted therapy approaches for key genes, proteins, and transcription factors (TFs) in TNBC.
  • To highlight the potential of siRNA-based therapies for improving TNBC prognosis and reducing mortality.

Main Methods:

  • Review of recent scientific literature on siRNA delivery systems for TNBC.
  • Discussion of targeted approaches utilizing nanomaterials for gene silencing in TNBC.
  • Analysis of bioengineered siRNA drugs for simultaneous gene downregulation.

Main Results:

  • Nanomaterial-based siRNA delivery platforms show promise for targeted TNBC therapy.
  • Targeting upregulated genes, proteins, and TFs in TNBC can disrupt pathways associated with poor prognosis.
  • Simultaneous gene silencing via bioengineered siRNA can significantly reduce TNBC progression.

Conclusions:

  • siRNA-based therapies, particularly when delivered via nanomaterials, represent a promising frontier for TNBC treatment.
  • Targeted gene silencing offers a strategy to overcome limitations of current TNBC therapies.
  • Advances in nanomedicine are crucial for developing effective and less toxic treatments for aggressive breast cancers.